Blog
RSS FeedPosted by Michael Wonder on 30 May 2024
ICER publishes evidence report on treatment for chronic obstructive pulmonary disease
30 May 2024 - Ensifentrine has a novel mechanism of action for an inhaled therapy; treatment would achieve common thresholds ...
Posted by Michael Wonder on 14 May 2024
ICER publishes evidence report on treatment for post-traumatic stress disorder
14 May 2024 - There are substantial uncertainties around the clinical trial results; given the inability to assess net benefit, ...
Posted by Michael Wonder on 09 May 2024
ICER releases draft evidence report on treatment for anaemia in myelodysplastic syndrome
9 May 2024 - Public comment period now open until 10 June 2024; requests to make oral comment during public ...
Posted by Michael Wonder on 10 Apr 2024
ICER releases draft evidence report on treatment for chronic obstructive pulmonary disease
10 April 2024 - Public comment period now open until 7 May 2024; requests to make oral comment during public ...
Posted by Michael Wonder on 09 Apr 2024
ICER publishes 2024 research protocol for assessing unsupported price increases on prescription drugs
9 April 2024 - Input period now open until 13 May 2024. ...
Posted by Michael Wonder on 26 Mar 2024
ICER releases draft evidence report on treatment for post-traumatic stress disorder
26 March 2024 - Public comment period now open until 22 April 2024; requests to make oral comment during public ...
Posted by Michael Wonder on 14 Mar 2024
ICER publishes final evidence report on treatments for paroxysmal nocturnal haemoglobinuria
13 March 2024 - Independent appraisal committee voted that current evidence is not adequate to demonstrate a net health benefit ...
Posted by Michael Wonder on 11 Mar 2024
ICER publishes final evidence report on treatment for schizophrenia
11 March 2024 - Independent appraisal committee voted that current evidence is not adequate to demonstrate superior net health benefits ...
Posted by Michael Wonder on 01 Feb 2024
ICER publishes evidence report on treatments for paroxysmal nocturnal haemoglobinuria
1 February 2024 - Iptacopan and danicopan are two first in class agents that provide important health benefits, but there ...
Posted by Michael Wonder on 27 Jan 2024
ICER publishes evidence report on treatment for schizophrenia
25 January 2024 - KarXT has a novel mechanism of action, but there are significant uncertainties regarding long term efficacy ...
Posted by Michael Wonder on 08 Jan 2024
ICER publishes final evidence report on treatment for pulmonary arterial hypertension
8 January 2024 - Independent appraisal committee voted that sotatercept demonstrated a net health benefit when compared to background therapy; ...
Posted by Michael Wonder on 04 Jan 2024
ICER to assess treatment for myelodysplastic syndrome
3 January 2024 - Report will be subject of CTAF meeting in July 2024; draft scoping document open to public ...
Posted by Michael Wonder on 11 Dec 2023
ICER identifies most significant 2022 US drug price hikes unsupported by new clinical evidence
11 December 2023 - Of 10 high expenditure drugs that had substantial 2022 net price increases, eight were not supported by ...
Posted by Michael Wonder on 05 Dec 2023
ICER releases draft evidence report on treatment for paroxysmal nocturnal haemoglobinuria
5 December 2023 - Public comment period now open until 9 January 2024; requests to make oral comment during public ...
Posted by Michael Wonder on 28 Nov 2023
ICER releases draft evidence report on treatment for schizophrenia
28 November 2023 - Public comment period now open until 22 December 2023; requests to make oral comment during public meeting ...